최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0622660 (2015-02-13) |
등록번호 | US-9610351 (2017-04-04) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 869 |
Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered
Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.
1. A synthetic peptide comprising the amino acid sequence Trp-(D)Pro-Ser-Phe-NH2 (SEQ ID NO: 3). 2. A synthetic peptide comprising the amino acid sequence Trp-(D)Ser-Ser-Phe-NH2 (SEQ ID NO: 4). 3. An inhalable, analgesic composition comprising a diketopiperazine, a synthetic peptide comprising the s
1. A synthetic peptide comprising the amino acid sequence Trp-(D)Pro-Ser-Phe-NH2 (SEQ ID NO: 3). 2. A synthetic peptide comprising the amino acid sequence Trp-(D)Ser-Ser-Phe-NH2 (SEQ ID NO: 4). 3. An inhalable, analgesic composition comprising a diketopiperazine, a synthetic peptide comprising the synthetic peptide of claim 1, and optionally, a pharmaceutically acceptable excipient. 4. An inhalable, analgesic composition comprising a diketopiperazine, a synthetic peptide comprising the synthetic peptide of claim 2, and optionally, a pharmaceutically acceptable excipient. 5. A pharmaceutical composition comprising the inhalable composition of claim 3 or 4 and a pharmaceutically acceptable carrier or excipient. 6. The pharmaceutical composition of claim 5, wherein the pharmaceutical carrier or excipient is selected from the group consisting of amino acids, sugars, and surfactants. 7. The pharmaceutical composition of claim 5, further comprising a diketopiperazine or a pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition of claim 7, wherein the diketopiperazine is 3,6-bis(N-fumaryl-4-aminobutyl)]-2,5, diketopiperazine. 9. The pharmaceutical composition of claim 8, wherein the composition comprises microparticles. 10. The pharmaceutical composition of claim 8, wherein the microparticles have a volumetric mean geometric diameter less than 8 μm in diameter. 11. The pharmaceutical analgesic composition of claim 8, wherein the composition comprises a dry powder, and the peptide comprises at least 0.25% of the weight of the composition. 12. A method for treating pain, comprising administering to a subject in need of treatment a therapeutically effective amount of the pharmaceutical composition of claim 9, using a dry powder drug delivery system. 13. The method of claim 12, wherein the dry powder drug delivery system comprises a dry powder inhaler comprising a container configured to hold said inhalable analgesic composition in a containment configuration and in a dosing configuration. 14. The method of claim 13, wherein the inhalable analgesic composition comprises a dry powder and wherein the peptide binds to an opiate receptor. 15. The method of claim 14, wherein the opioid receptor comprises a μ opioid receptor, a δ opioid receptor, or a κ opioid receptor, or combinations of receptors thereof, of cells in the central or peripheral nervous systems.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.